Project Grant R03CA300928
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Alabama, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,682 to The Trustees of the University of Pennsylvania to develop "tumor-site activated T cell redirecting autoantibodies" - a novel cancer immunotherapy approach. The award period runs from March 1, 2025 to February 28, 2027. The project aims to leverage a patient's own anti-tumor autoantibodies to enhance the immune system's ability to target and clear cancer cells,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $409,158 to the University of Missouri System to evaluate the effectiveness of an oncolytic adenovirus, OADSA-4-1BBL, alone or combined with anti-PD1 blockade in an immunocompetent lung cancer mouse model. The goal is to develop a novel oncolytic adenovirus that preferentially infects and kills lung cancer cells by targeting the transferrin receptor. The central hypothesis is that...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This federal Project Grant award of $398,997 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a novel antibody therapy targeting the immune checkpoint receptor LAIR1 (Leukocyte-Associated Immunoglobulin-Like Receptor 1) to overcome tumor-associated macrophage (TAM)-mediated immunosuppression in cancer. The key goals of this 1-year project are to: 1) validate the in vitro binding, specificity, and functional blocking activity of a humanized anti-LAIR1...
- This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This $386,279 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a microfluidic device for personalized immunotherapy screening on core needle biopsies from cancer patients. The project will: Create a "core needle biopsy" microfluidic cassette and protocols for functional immune assays, and Validate the microfluidic approach for screening immune checkpoint blockade therapy using core needle biopsies from...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...